Needham, MA, September 11, 2012 --(PR.com
)-- Cambridge Healthtech Institute (CHI) today announced details of ten breakout discussion groups, each to be hosted by a different moderator, at its fourth annual Immunogenicity Summit 2012 to be held on October 10-12, 2012 at the DoubleTree by Hilton Hotel in Bethesda, MD. Approximately 300 delegates from over 50 organizations will attend. This 2-part event will cover developments in assay technologies, risk assessment, regulatory guidance and means of predicting and avoiding immunogenicity.
Breakout Discussions Part One, Wednesday October 10:
Table 1: Challenges in Developing Neutralizing Antibody Assays
Moderator: Deborah Finco, Ph.D., Senior Principal Scientist, Immunotoxicology COE, Pfizer, Inc.
Table 2: Dealing with Pre-existing Positive ADA Activity in Study Patients
Moderator: Jim McNally, Ph.D., Senior Principal Scientist, Pfizer, Inc.
Table 3: Practical Application of Immunogenicity Pre-Clinical Risk Assessment
Moderator: Paul Chamberlain, NDA Advisory Board
Table 4: Detection of Immune Complexes and Their Impact on Immunogenicity Assessment
Moderator: Steve J. Swanson, Ph.D., Executive Director, Medical Sciences, Clinical Immunology, Amgen, Inc.
Table 5: Immunogenicity Testing During Clinical Trials
Moderator: Frank F. Weichold, M.D., Ph.D., Director, Clinical Pharmacology and DMPK, Translational Science, MedImmune, LLC
Table 6: IgE Anti-drug Assay Development and Validation
Jörgen Dahlström, Ph.D., MBA, Scientific Director, ImmunoDiagnostics, Thermo Fisher Scientific
Breakout Discussions Part Two, Friday October 12:
Table 1: Product-related Factors that Contribute to Immunogenicity
Moderator: Wim Jiskoot, Ph.D., Professor, Division of Drug Delivery Technology, Leiden University
Table 2: To what Extent can Immunogenicity Prediction affect the Clinical Strategy?
Moderator: Timothy Hickling, Ph.D., Associate Research Fellow, PDM Immunogenicity Sciences, Pfizer, Inc.
Table 3: Immune Tolerance Approaches
Moderator: Amy Rosenberg, M.D., Director, Therapeutic Proteins, CDER/FDA
Table 4: Relevance of Animal Models for Predicting the Immunogenicity of Therapeutic Proteins
Jack Ragheb, M.D., Ph.D., Principal Investigator, Immunology, Therapeutic Proteins, CDER/FDA
Delegates attending the Immunogenicity Summit 2012 may track-hop to the sessions at CHI’s concurrent event, PK/PD of Novel Constructs: Bispecific Antibodies, Antibody Fragments, and ADCs.
To inquire about sponsoring and/or exhibiting, contact Tim McLucas, 781-972-1342, email@example.com.
Writers and editors are encouraged to attend. To request a press pass, contact Lisa Scimemi at firstname.lastname@example.org.
About Cambridge Healthtech Institute
Cambridge Healthtech Institute (CHI) is the preeminent life science network for leading researchers and business experts from top pharmaceutical, biotech and academic organizations. CHI’s portfolio of products includes Cambridge Healthtech Institute Conferences, Insight Pharma Reports, Barnett International, Cambridge Marketing Consultants, Cambridge Meeting Planners and Cambridge Healthtech’s Media Group, which includes numerous e-newsletters as well as Bio-IT World magazine.
Founded in 1992, Cambridge Healthtech Institute strives to develop quality information sources that provide valuable new insights and competing points of view while offering balanced coverage of the latest developments. Basic research related to commercial implications is covered, with heavy emphasis placed on end-user insights into new products and technology as well as coverage on the strategy behind the business.
Cambridge Healthtech Institute